Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Inclusion Criteria

• •The subject has a histologically confirmed diagnosis of MTC that cannot be removed by surgery, is locally advanced, or has spread in the body.
• •The subject is at least 18 years old.
• •The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.
• •The subject has documented worsening of disease (progressive disease) at screening compared with a previous CT scan or MRI image done within 14 months of screening.
• •The subject has recovered from clinically significant adverse events (side effects) due to any other medications that were administered prior to randomization.
• •The subject has adequate organ and bone marrow function.
• •Subjects who are sexually active (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments.
• •The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed ≥ 2 years previously) and currently has no evidence of malignancy (unless non-melanoma skin cancer or an early form of cervical cancer).
• •Female subjects of childbearing potential must have a negative pregnancy test at screening.